Prof. Patricia LoRusso
Organization: Yale University
Project Name: Phase 2 Study of PARP inhibition and Anti-PD-L1 Therapy in BRCAmt TNBC
Funding Year: 2018
Project period: 2 years
Phase 2 Study of PARP inhibition and Anti-PD-L1 Therapy in BRCAmt TNBC
The clinical trial to which this proposal is attached is a randomized, open-label phase II trial exploring the effects of the anti-PD-L1 human monoclonal antibody atezolizumab with the PARP inhibitor Veliparib either alone or in combination in 100 patients with BRCA1/2 TNBC.
This grant will evaluate the mutational load, neoantigens, and anti-tumor immune effects of PARP inhibition and immune-stimulation and determine the possible connection between the biomarkers and patient performance after treatment.